Related Experiment Video
Updated: Aug 9, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
[An attempt at differentiating between medullary and extramedullary derived B-cell chronic lymphocytic leukemia]
Z M Rupniewska1, M Wach, J Roliński
1Klinika Hematologii, Akademia Medyczna w Lublinie.
Insights
This study differentiates chronic lymphocytic leukemia from small lymphocyte lymphoma by analyzing CD5+ cell percentages in blood and bone marrow. Higher CD5+ cells in bone marrow suggest leukemia, while higher levels in peripheral blood indicate lymphoma.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- B-cell chronic lymphocytic leukemia (CLL) is a heterogeneous lymphoid malignancy.
- Distinguishing CLL from other small B-cell lymphomas is crucial for accurate diagnosis and treatment.
- Immunophenotyping of peripheral blood and bone marrow aids in disease characterization.
Purpose of the Study:
- To compare lymphocyte immunological phenotypes in peripheral blood and bone marrow of CLL patients.
- To investigate the utility of CD5 antigen and mouse erythrocyte rosette (MER) formation in differentiating CLL subtypes.
- To correlate cell marker percentages with tumor cell localization.
Main Methods:
- Comparative analysis of peripheral blood and bone marrow samples from 14 CLL patients.
- Estimation of B cell markers: surface immunoglobulin light chains (lambda or kappa), CD5 antigen, and mouse erythrocyte rosette (MER) formation.
- Patient stratification into three groups based on tumor cell distribution (lymphoid structures vs. bone marrow).
Main Results:
- CD5+ cell percentages differed significantly between peripheral blood and bone marrow based on tumor localization.
- Group I (lymphoid/lymph node dominance) showed higher CD5+ cells in peripheral blood (38.5%) vs. bone marrow (26.7%).
- Group II (bone marrow dominance) exhibited higher CD5+ cells in bone marrow (64.3%) vs. peripheral blood (44.8%), P < 0.01.
- MER+ cell behavior paralleled CD5+ cells, but no direct correlation was found within groups.
Conclusions:
- CD5+ cell distribution in peripheral blood versus bone marrow can help differentiate CLL from the leukaemic phase of small lymphocyte lymphoma.
- Domination of CD5+ cells in bone marrow suggests CLL.
- Domination of CD5+ cells in peripheral blood indicates the leukaemic phase of small lymphocyte lymphoma.
Abstract:
A comparative research on lymphocyte immunological phenotypes in peripheral blood and bone marrow was carried out on 14 patients with B-cell chronic lymphocytic leukaemia. Three types of B cell markers were estimated: 1-light chains (lambda or kappa) on the surface of cells, 2-CD5 antigen, 3-capability of forming mouse erythrocyte rosettes (MER); the last two markers are mostly characteristic of leukaemic cells. The patients were divided into 3 groups according to the localisation of the main mass of tumorous cells: group I-the patients, whose clinical picture was dominated by the infiltration of lymphoid structures of the abdominal cavity and/or with massive infiltration of peripheral lymph nodes; group II-the patients, whose clinical picture was dominated by the infiltration of bone marrow; group III-the intermediate-patients with large mass of tumor in lymphoid structures and with bone marrow insufficiency symptoms. In most of the patients of group I, the percentage of CD5+ cells in peripheral blood was higher than the one in bone marrow (arithmetic means were 38.5% for blood and 26.7% for marrow). It was the reverse in group II (the means were 44.8% for blood and 64.3% for marrow, P < 0.01). The percentage in group III was similar to that of group I (the means-48% for blood and 29.25% for marrow). No correlation between the percentage of CD5+ and MER+ cells was found in respective groups of the patients although the last marker behaved similarly to CD5. The results obtained suggest that while estimating percentages of CD5+ cells in peripheral blood and bone marrow, one can differentiate between chronic lymphocytic leukaemia (with domination of CD5+ cells in bone marrow) and leukaemic phase of small lymphocyte lymphoma (with domination of CD5+ cells in peripheral blood).
More Related Videos
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11:39Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019